Skip to main content

Advertisement

Table 5 Prevalence of intermediate states of hyperglycemia,* baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), n = 15102, 2008-2010

From: High prevalence of diabetes and intermediate hyperglycemia – The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)

  Total Men (n = 6885) Women (n = 8217)
  n % 95% CI n % 95% CI n % 95% CI
IGT 3064 20.3 19.7-20.9 1455 21.1 20.2-22.1 1609 19.6 18.7-20.4
IFG (WHO) 2886 19.1 18.5-19.7 1680 24.4 23.4-25.4 1206 14.7 13.9-15.4
IFG (ADA) 7946 52.6 51.8-53.4 4050 58.8 57.7-60.0 3896 47.4 46.3-48.5
Intermediate HbA 1C (ADA ) ** 2431 16.1 15.5-16.7 1011 14.7 13.9-15.5 1420 17.3 16.5-18.1
Intermediate HbA 1C ≥6.0%*** 1049 7.0 6.5-7.4 433 6.3 5.7-6.9 616 7.5 6.9-8.1
IFG (WHO) or IGT 4684 31.0 30.3-31.8 2406 35.0 33.8-36.1 2278 27.7 26.8-28.7
IFG (ADA) or IGT 8472 56.1 55.3-56.9 4217 61.3 60.1-62.4 4255 51.8 50.7-52.9
IFG (WHO) or Intermediate HbA 1C (ADA) 4514 29.9 29.2-30.6 2266 32.9 31.8-34.0 2248 27.4 26.4-28.3
IFG (ADA) or Intermediate HbA 1C (ADA) 8532 56.5 55.7-57.3 4210 61.2 60.0-62.3 4322 52.6 51.5-53.7
IGT, IFG (WHO) or Intermediate HbA 1C (ADA) 5929 39.3 38.5-40.0 2852 41.4 40.3-42.6 3077 37.5 36.4-38.5
IGT, IFG (ADA) or Intermediate HbA 1C (ADA) 8971 59.4 58.6-60.2 4356 63.3 62.1-64.4 4615 56.2 55.1-57.2
  1. *After excluding diabetes defined by a self report, medication use or elevated HbA1C, fasting plasma glucose or plasma glucose 2 h after a glucose load.
  2. **HbA1C ≥5.7% (≥38.8 mmol).
  3. ***HbA1C ≥6.0% (≥42.1 mmol).
  4. IGT = impaired glucose tolerance; IFG = impaired fasting glucose; ADA = American Diabetes Association; WHO = World Health Organization; HbA1C = glycated hemoglobin.